Call Us Contact Us
+44 1494 818 000     Online Enquiry
Lines open
Monday to Thursday
08:30 to 18:00
Friday
08:30 to 17:30
Pharmaceutical | Medical Devices | Scientific | Consumer Healthcare | Dental | Animal Health
Healthcare Communications | Pharmaceutical Executive | Medical Executive | Tech PR | Scientific Executive
         
Latest Jobs
Exclusive vacancies may not be shown here, please contact on +44 or for more information.
Have you registered?
Once you register you can see additional job details, save jobs, track your applications and manage e-lert preferences.

Register now
Testimonials
I want to thank Zenopa for their time and efforts in helping me during my job search, you have given me the extra confidence I need to keep me pro-active in my search.
Mohammed, 2011

Cephalon obtains option for Alba celiac disease drug

10 February 2011 00:00 in Pharmaceutical Company Product News


Cephalon has signed an agreement that gives the company the option to purchase a potentially promising new treatment for celiac disease from Alba Therapeutics.

The firm has paid Alba a $7 million upfront fee and will be offering funding support for a phase IIb trial of the drug in question, a tight junction modulator known as larazotide acetate.

Under the terms of the deal, Cephalon can acquire all assets relating to the treatment at any time prior to the end of a specified period after data from this trial has been published by paying Alba a further $15 million.

Kevin Buchi, Cephalon's chief executive officer, said it has purchased the option based on the encouraging trial data it has evaluated for the drug thus far.

"If successful, larazotide acetate will add to our pipeline in immunology and has the potential to be the first pharmacologic therapy available to treat patients who endure this often serious condition," he said.

Last month, the company published data from a phase IV study of the drug Nuvigil, demonstrating its efficacy in combating sleep disorders.ADNFCR-8000103-ID-800396762-ADNFCR

Other news stories from 10/02/2011

Related news

Read more in the Zenopa News Archive

How this news is generated

Story collated for Zenopa by the Axonn News Agency



                    
© Copyright 2014 Zenopa Ltd